The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Development of Progressive Pre-clinical Models of PD, 2006LRRK2 and PD Genetic Pre-clinical Models
The cause of Parkinson's in most patients is unknown, but in a small percentage of cases (three to five percent), mutation in a specific gene is causal. Several genes have been conclusively linked to...
-
Development of Progressive Pre-clinical Models of PD, 2006Inflammatory Stimuli as 'Second-Hit' Triggers for Development of Progressive Nigral Degeneration
Parkin and DJ-1 knockout mice model the recessively inherited loss-of-function mutations in these genes that cause human parkinsonism. Despite significant nigrostriatal dysfunction in both knockout...
-
Development of Progressive Pre-clinical Models of PD, 2006The PD Pre-Clinical Model: A Progressive Model of Parkinson's Disease with Key Pathology and Behavior Caused by Targeting Mitochondrial Function in Dopamine Neurons
Recent research suggests that there can be genetic causes of Parkinson's disease. In several forms of the disease, these genetic disturbances appear to compromise function of the cells' energy...
-
Development of Progressive Pre-clinical Models of PD, 2006Rat Transgenic Models for Autosomal Dominant PD via BAC Technology
Animal models are crucial in the mechanistic study of Parkinson's disease and therapeutic development. However, a severe and unfortunate roadblock is that to date no genetic mammalian models have...
-
Development of Progressive Pre-clinical Models of PD, 2006Two-Hit Pre-clinical Models for Parkinson’s Disease
Despite recent advances in Parkinson's disease genetics, the animal models based on identified genetic defects have not largely emulated the progressive nigral neuron degeneration that characterizes...
-
Target Validation, 2006Granulocyte-colony Stimulating Factor (G-CSF) as a Neuroprotective Therapy for Parkinson's Disease
Although a relatively large number of drugs is available to alleviate the symptoms of Parkinson's disease, there is no therapy available so far that halts or delays the disease progression. This...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.